Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.95 |
| ▸ | PGR | P06401 | 4/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.95 |
| ▸ | USP2 | O75604 | 3/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | MMP1 | P03956 | 10/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.72 |
| ▸ | PPARG | P37231 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | DRD2 | P14416 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151466 | 1.00 | NR3C1 (0.95) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL2933292 | 1.00 | NR3C1 (0.95) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL2940259 | 1.00 | NR3C1 (0.95) | NR3C1PGRCYP3A4USP2MEN1 | |
| SCHEMBL93888 | 1.00 | NR3C1 (0.95) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL14339607 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL16243364 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL9768484 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL11051241 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Dexamethasone Valarate SCHEMBL124723 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL14339612 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3993715-B1 | IMPLANTATION NEEDLE FOR INSERTING A SUBCUTANEOUSLY INSERTABLE ELEMENT INTO A BODY TISSUE | HOFFMANN LA ROCHE (CH) | 2024-04-17 | — | — | EP | claimed |
| US-20230320979-A1 | OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION | SANTEN SAS (FR) | 2023-10-12 | — | — | US | claimed |
| EP-4213804-A1 | OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION | Santen SAS (FR) | 2023-07-26 | — | — | EP | claimed |
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | claimed |
| CN-116367824-A | Oil-in-water emulsion for intravitreal administration | 桑腾股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| WO-2022058325-A1 | OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION | SANTEN SAS (FR) | 2022-03-24 | — | — | WO | claimed |
| EP-2914311-B1 | METHOD OF TREATING VASCULAR DISEASE IN DIABETIC PATIENTS | ABBOTT CARDIOVASCULAR SYSTEMS INC (US) | 2017-06-28 | — | — | EP | claimed |
| EP-2914311-A1 | METHOD OF TREATING VASCULAR DISEASE IN DIABETIC PATIENTS | Abbott Cardiovascular Systems Inc. (US) | 2015-09-09 | — | — | EP | claimed |
| US-9060923-B2 | Method of treating vascular disease in diabetic patients | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2015-06-23 | — | — | US | claimed |
| WO-2014070322-A1 | METHOD OF TREATING VASCULAR DISEASE IN DIABETIC PATIENTS | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-05-08 | — | — | WO | claimed |
| US-20140127278-A1 | Method Of Treating Vascular Disease In Diabetic Patients | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2014-05-08 | — | — | US | claimed |
| US-8623852-B2 | Topical methods and compositions for the treatment of eye diseases and conditions | SANTEN SAS (FR) | 2014-01-07 | — | — | US | claimed |
| US-20130303496-A1 | Method Of Treating Vascular Lesions | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2013-11-14 | — | — | US | claimed |
| EP-2564853-A1 | Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders | Novagali Pharma S.A. (FR) | 2013-03-06 | — | — | EP | claimed |
| US-20100286065-A1 | TOPICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES AND CONDITIONS | NOVAGALI PHARMA SA (FR) | 2010-11-11 | — | — | US | claimed |
| EP-2229174-A1 | COMPOSITIONS COMPRISING CORTICOSTEROID PRODRUG SUCH AS DEXAMETHASONE PALMITATE FOR THE TREATMENT OF EYE DISORDERS | Novagali Pharma S.A. (FR) | 2010-09-22 | — | — | EP | claimed |
| WO-2009071594-A1 | COMPOSITIONS COMPRISING CORTICOSTEROID PRODRUG SUCH AS DEXAMETHASONE PALMITATE FOR THE TREATMENT OF EYE DISORDERS | NOVAGALI PHARMA SA (FR) | 2009-06-11 | — | — | WO | claimed |
| US-20240358829-A1 | Lymphocyte Population and Methods for Producing Same | AVM BIOTECHNOLOGY, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20070280995-A1 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye | NOVAGALI PHARMA SA (FR) | 2007-12-06 | — | — | US | disclosed |
| WO-2007138113-A1 | USE OF A STEROID PRODRUG FOR THE TREATMENT OF DISEASE OF THE POSTERIOR SEGMENT OF THE EYE | NOVAGALI PHARMA SA (FR) | 2007-12-06 | — | — | WO | disclosed |